BioLife Q4 rev $32.7M (-26% YoY); guides 2024 rev $95.5-100M ex-freezer; adj EBITDA positive

BIOLIFE SOLUTIONS INC

2023-FY EPS reported -$1.52 revenue$143,271,000

Q4 GAAP net loss $13.4M ($0.30 loss/share) vs $49.2M loss ($1.15) in Q4 2022.
Cell Processing platform Q4 rev $14.8M, down 27% YoY but up 11% sequentially.
Freezer divestiture underway; expects sale by end of Q1 2024.
2024 revenue guidance $95.5-100.0M (ex-freezer); expects full-year positive adjusted EBITDA.
Biopreservation media embedded in 14 approved CGT therapies as of Feb 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOLIFE SOLUTIONS INC updated its the fourth quarter and year ended December 31, 2023 guidance (initiated).

Period: the fourth quarter and year ended December 31, 2023
Guidance: initiated
Result: reported results

Exact text from the filing

On February 29, 2024, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing financial results and operational highlights for the fourth quarter and year ended December 31, 2023.

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOLIFE SOLUTIONS INC filing history →

Source: SEC EDGAR

accession 0001628280-24-007964

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.